Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genome-wide analysis of 944 133 individuals provides insights into the etiology of haemorrhoidal disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pattern recognition receptor polymorphisms in early periodontitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Lewis and AB0 blood group-phenotypes in periodontitis, cardiovascular disease, obesity and stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Casper Steenholdt
  • Jørn Brynskov
  • Ole Østergaard Thomsen
  • Lars Kristian Munck
  • Jan Fallingborg
  • Lisbet Ambrosius Christensen
  • Gitte Pedersen
  • Jens Christian William Kjeldsen
  • Bent Ascanius Jacobsen
  • Anne Sophie Oxholm
  • Jakob Kjellberg
  • Klaus Bendtzen
  • Mark Andrew Ainsworth
View graph of relations
Although the reasons for secondary loss of response to infliximab (IFX) maintenance therapy in Crohn's disease vary, dose intensification is usually recommended. This study investigated the cost-effectiveness of interventions defined by an algorithm designed to identify specific reasons for therapeutic failure.
Original languageEnglish
JournalGut
Volume4
Issue number63
Pages (from-to)919
Number of pages9
ISSN0017-5749
DOIs
Publication statusPublished - 2014

ID: 42508094